Navigation Links
Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
Date:11/21/2011

CAMBRIDGE, England, November 21, 2011 /PRNewswire/ --

Phase I Single Dose Study Data Demonstrate Ideal Pharmacokinetic Profile and Excellent Safety and Tolerability

Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines, today announces that the multiple ascending dose Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated.

The trial is a randomised, placebo controlled Phase I study to investigate the pharmacokinetics, safety and tolerability of orally administered multiple dose regimens of CNV2197944 in both young and elderly volunteers. CNV2197944 is proposed for development initially as a treatment for neuropathic pain and pain associated with osteoarthritis. The study is expected to conclude in 2Q 2012.

The first human single ascending dose Phase I study with orally administered CNV2197944 was recently completed. CNV2197944 was shown to be well absorbed, with an ideal pharmacokinetic profile for the target indication of chronic pain. The compound was well tolerated, with an excellent safety profile.

Clive Dix, Chief Executive Officer of Convergence Pharmaceuticals, commented: "We are really excited to be advancing on schedule to a multiple ascending dose study with this novel, first-in-class treatment for chronic pain.  The data we have seen so far gives us great confidence that CNV2197944 will be a safe and effective long term treatment for chronic pain."

CNV2197944 - a first in class molecule with potential to be a first in class treatment

CNV2197944 is a novel, small molecule, state-dependent calcium channel blocker, designed to selectively inhibit highly active Cav2.2 channels. Preclinical studies demonstrated that CNV2197944 could have analgesic potential for a broad range of chronic pain conditions. Extensive safety and toxicology studies
'/>"/>

SOURCE Convergence Pharmaceuticals Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802
2. Nano-Bio-Info-Cogno Revolutions to be Explored at Convergence08 Unconference - Forecaster Paul Saffo to Keynote
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. Access Pharmaceuticals Signs Agreement for CobaCyte® and CobOral® in RNAi Therapeutic Delivery
5. Radient Pharmaceuticals Announces Proxy Resolutions Approved at Special Meeting of Stockholders
6. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
7. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Credit Suisse Healthcare Conference on November 9, 2011
9. Optimer Pharmaceuticals to Present at 20th Annual Credit Suisse Healthcare Conference
10. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results and Recent Operational Highlights
11. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... 2, 2015 College of DuPage students ... gaining invaluable real-world experiences while serving biophysics internships at ... The students will be working as a part ... at IIT. The internship came about from a ... Physics; Dr. Kathy Finan , Biology; and Dr. ...
(Date:7/2/2015)... Scotland , July 2, 2015 ... Bio-tech procurement company Amici Procurement has chosen ... to help it move to Office 365. ... provides small to medium-sized companies in the bio-tech ... all aspects of the purchasing cycle to help them ...
(Date:7/2/2015)... ... July 02, 2015 , ... In’Tech Medical SAS ( http://www.intech-medical.com ... announced today the acquisition of Turner Medical, Inc ., thus becoming a ... to the Spine Industry. The acquisition of Turner Medical ideally supplements In’Tech Medical’s ...
(Date:7/1/2015)... N.C. and PARIS ... firm AgBiome, and Genective, key developer of biotech ... the discovery of new generations of insect control ... insect control to counter the realities of advancing ... Genective, aligning AgBiome,s unique insect control technology with ...
Breaking Biology Technology:COD Students Participate in Prestigious Summer Internships 2Biotech Procurement Company Moves to Office 365 with iomart 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3AgBiome and Genective collaborate to create novel insect-resistant crops 2
... Corporation, a company enabling a new generation of molecular ... Mo lecule A rray (SiMoA ™ ) ... measure biomarkers of inflammation from patients with Crohn,s disease. ... was possible using Quanterix,s high sensitivity digital ELISA, allowed ...
... small package. For instance, these tiny cylinders of carbon ... than a metal conductor of the same size. It,s ... future nanoscale electronics. Butnot so fast. Recent tests ... suggest device reliability is a major issue. Copper ...
... CBI is pleased to announce the full agenda for ... being held September 20-22, 2011 in Philadelphia, PA. The ... from Celgene, Covidien, FDA, Forest, Ironwood Pharmaceuticals, Merck, NIH, ... Attendees have the opportunity to customize their congress experience ...
Cached Biology Technology:Quanterix Digital ELISA Measures Low Abundance Biomarkers of Inflammation in Crohn's Disease 2NIST uncovers reliability issues for carbon nanotubes in future electronics 2FDA, NIH to Speak at CBI's 14th Annual Registries and Post-Approval Studies Congress 2
(Date:6/30/2015)... NEW YORK , June 30, 2015 To ... biometric security provider HYPR Corp. announced today the addition of ... will serve as board advisor and David Raviv ... to the team underscore HYPR Corp.,s commitment to providing the ... , Dimitri Sirota co-founded Layer 7 Technologies, a ...
(Date:6/26/2015)... SPRINGVILLE, Utah , June 26, 2015 ATL ... assemblies and devices with specialties in single use solutions, headquartered ... acquisition of MedConx, Inc. (a California ... , and San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing ...
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., ... patent by the United States Patent and Trademark Office ... This process leverages TAKE Solutions, Clinical Accelerators to reduce ... 50% (when compared to standardization without the accelerators), thus ... At the heart of the ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2TAKE Solutions Awarded Patent By USPTO 2
... implant such as a new hip or pacemaker with nanosized ... the University of Gothenburg, Sweden, can now explain why: they ... the International Journal of Nanomedicine . "Activation of ... common reasons for an implant being rejected," explains Professor Hans ...
... of ageing on the immune system received a boost ... (BBSRC) announced investment in a new 3.6 million research ... from the Babraham Institute with partners from the University ... The team hopes to illuminate a fundamental but little ...
... Livermore National Laboratory Geochemist Tom Guilderson has been ... prestigious Ernest Orlando Lawrence Award, Energy Secretary Steven ... for ground-breaking radiocarbon measurements of corals, advancements in ... processes revealing past climate variability, and the explanation ...
Cached Biology News:Cobblestones fool innate immunity 2New research aims to shed light on how aging affects immunity 2New research aims to shed light on how aging affects immunity 3Geochemist Tom Guilderson wins E.O. Lawrence Award for radiocarbon work 2
FRACTALKINE [Human] (Recombinant)...
... Operating head automatically rises at the end of determination; triple-point calibration verification; refrigerator eliminates need for pumps ... ... ... ...
... System with the xPONENT Software Interface ... multi-analyte assays using Upstate's Beadlyte® reagents. ... user friendly xPONENT software developed by ... templates for commercial or home-made multiplex ...
2,4,6-Trinitrophenyl hapten is conjugated to Bovine Gamma Globulin (BGG) through lysine by amide bonds....
Biology Products: